---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-006538"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:49:58.400597+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Monopar reports positive preclinical imaging data for MNPR-101-Lu in pancreatic cancer model

## Summary
- SPECT imaging shows high specificity and durable uptake of MNPR-101-Lu in tumor relative to normal tissue in human pancreatic cancer xenograft model.
- Data help explain near complete tumor elimination observed after single injection of therapeutic radioisotopes bound to MNPR-101 in prior studies.
- MNPR-101-Lu uses Lutetium-177, same therapeutic radioisotope as commercially successful Pluvicto and Lutathera.
- Phase 1 dosimetry trial for diagnostic counterpart MNPR-101-Zr recently cleared by HREC in Australia for advanced cancer patients.

## SEC filing metadata
- accession: 0001437749-24-006538
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924006538/0001437749-24-006538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924006538/mnpr20240304_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-006538
- JSON: https://secwatch.observer/filing/0001437749-24-006538.json
- Plain text: https://secwatch.observer/filing/0001437749-24-006538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.